Abstract 3715
Background
The main objective of this project is to develop a mobile application (APP) for monitoring and controlling the management of the therapeutic regime in this group of people, with a view to strengthening communication among patients and health professionals, favoring adherence to therapeutic indications and responding, in a timely manner and in a proactive manner, to the symptoms or complications that may arise associated with the disease, thereby improving the efficacy of the therapy, preventing complications and improving its perception of health and quality of life. In fact, health interventions must transform behavior towards the desired improvement and empowerment of the person, thus facilitating self-management. Its final presentation will be on the form of an APP, which will improve the well-being and quality of life of people with cancer, bringing gains in efficiency and health outcomes, broadening the sense of the adequacy of policies of health. The expected results with the implementation of this APP are: improve and monitor patient adherence to oral and supportive therapies; to prevent, the appearance of complications or symptoms associated with the treatment, through preventive indications of self-care (green alert level); improve patients responses, through self-care uncontrolled complications (yellow alert level); signaling to the patient and health services, uncontrolled symptoms with high severity (red alert level); improve the efficiency of health teams with regard to self-management of the disease and produce and disseminate knowledge in oncology. At this time the project is already at an advanced stage of development. Systematic reviews of the literature were developed to support the interventions included in the APP. The interventions were categorized by the two levels of self-care and were submitted to expert evaluation using the Delphi technique.
Trial design
Systematic reviews of the literature were developed to support the interventions included in the APP. The interventions were categorized by the two levels of self-care and were submitted to expert evaluation using the Delphi technique. The project has already been tested on an initial sample of 40 patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2901 - IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients
Presenter: Emilio Giunta
Session: Poster Display session 3
Resources:
Abstract
2306 - Multiplex Chromogenic Immunohistochemistry (IHC) for Spatial Analysis of Checkpoint-Positive Tumor Infiltrating Lymphocytes (TILs)
Presenter: Scott Ely
Session: Poster Display session 3
Resources:
Abstract
1678 - The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: a meta-analysis of randomized clinical trials.
Presenter: Alberto Carretero-Gonzalez
Session: Poster Display session 3
Resources:
Abstract
5138 - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma
Presenter: Kye Jin Park
Session: Poster Display session 3
Resources:
Abstract
5800 - Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumor microenvironment of mesothelioma
Presenter: Carmen Ballesteros-Merino
Session: Poster Display session 3
Resources:
Abstract
5736 - Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): real world data from 2 university hospitals in Spain
Presenter: Juan Felipe Cordoba Ortega
Session: Poster Display session 3
Resources:
Abstract
5645 - Evaluating Lung CT Density Changes Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Thoracic Radiotherapy (TRT) alone or TRT Followed by Combined Ipilimumab (IPI) and Nivolumab (NIVO).
Presenter: Kujtim Latifi
Session: Poster Display session 3
Resources:
Abstract
1540 - Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas
Presenter: Zoran Gatalica
Session: Poster Display session 3
Resources:
Abstract
4538 - Can we improve patient selection for phase 1 clinical trials (Ph1) based on Immuno-Oncology score prognostic index (VIO)?
Presenter: Ignacio Matos Garcia
Session: Poster Display session 3
Resources:
Abstract
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract